14,035 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Bought by Natixis Advisors L.P.

Natixis Advisors L.P. bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,035 shares of the company's stock, valued at approximately $881,000.

A number of other large investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its position in Vaxcyte by 1,005.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 22,603 shares of the company's stock valued at $1,419,000 after buying an additional 20,558 shares during the last quarter. Mutual of America Capital Management LLC acquired a new position in shares of Vaxcyte in the 4th quarter valued at approximately $3,035,000. Wellington Management Group LLP boosted its stake in shares of Vaxcyte by 3.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company's stock valued at $234,442,000 after buying an additional 167,501 shares during the last quarter. UBS Group AG grew its position in shares of Vaxcyte by 62.2% during the third quarter. UBS Group AG now owns 74,305 shares of the company's stock worth $3,788,000 after buying an additional 28,483 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Vaxcyte by 0.6% in the third quarter. Vanguard Group Inc. now owns 8,284,246 shares of the company's stock worth $422,331,000 after buying an additional 47,872 shares during the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Needham & Company LLC reissued a "buy" rating and set a $95.00 price objective on shares of Vaxcyte in a report on Thursday, May 9th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Vaxcyte in a research note on Thursday, May 9th.

Insider Activity at Vaxcyte

In related news, CEO Grant Pickering sold 15,000 shares of the business's stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $61.92, for a total transaction of $928,800.00. Following the sale, the chief executive officer now owns 477,847 shares of the company's stock, valued at $29,588,286.24. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $61.27, for a total value of $490,160.00. Following the transaction, the chief financial officer now owns 95,679 shares in the company, valued at $5,862,252.33. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Grant Pickering sold 15,000 shares of the stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $61.92, for a total value of $928,800.00. Following the sale, the chief executive officer now owns 477,847 shares of the company's stock, valued at approximately $29,588,286.24. The disclosure for this sale can be found here. Insiders have sold a total of 63,294 shares of company stock worth $4,254,105 in the last three months. 3.10% of the stock is owned by company insiders.

Vaxcyte Stock Down 1.2 %

NASDAQ PCVX traded down $0.88 during trading hours on Friday, hitting $74.57. The company had a trading volume of 688,017 shares, compared to its average volume of 803,213. The firm has a market cap of $8.11 billion, a P/E ratio of -17.42 and a beta of 0.94. Vaxcyte, Inc. has a fifty-two week low of $44.20 and a fifty-two week high of $82.04. The business has a fifty day simple moving average of $65.76 and a 200-day simple moving average of $63.40.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.28. Equities analysts forecast that Vaxcyte, Inc. will post -3.96 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.